GH
Guardant Health, Inc.
25.79
USD
This page is just a preview of the data found in TrendSpider’s full version
Guardant Health, Inc. stock is up 19.51% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 5 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 5 PUTs, 5 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 19 Oct 17:36 | 19 Jan, 2024 | 25.00 | 259 | ||
| 15 Nov 16:38 | 17 Jan, 2025 | 12.50 | 5 | ||
| 16 Nov 20:50 | 17 Jan, 2025 | 15.00 | 12 | ||
| 21 Nov 18:10 | 17 Jan, 2025 | 20.00 | 31 | ||
| 24 Nov 17:07 | 19 Apr, 2024 | 30.00 | 743 | ||
| 24 Nov 17:08 | 19 Apr, 2024 | 30.00 | 743 | ||
| 29 Nov 15:11 | 19 Apr, 2024 | 20.00 | 101 | ||
| 30 Nov 17:58 | 17 Jan, 2025 | 20.00 | 481 | ||
| 30 Nov 19:20 | 19 Jan, 2024 | 25.00 | 784 | ||
| 30 Nov 19:29 | 19 Jan, 2024 | 25.00 | 784 |
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, LDT, CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible. Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients.
